Search
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesProducts: RUPATADINA DOC GENERICITucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with trastuzumab and capecitabine in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tuca...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTreosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigationalTreosulfan is a prodrug alternative to busulfan for myeloablative conditioning prior to hematopoietic stem cell transplantation. It was approved by the EMA in June 2019 and by the FDA in January 2025 for use in combination with fludarabine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was ap...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBryostatin 1
go.drugbank.com/drugs/DB11752InvestigationalBryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAZD-1305
go.drugbank.com/drugs/DB11766InvestigationalAZD1305 has been used in trials studying the treatment and basic science of Atrial Flutter, Atrial Fibrillation, and Left Ventricle Function.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigationalSarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sariluma...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates